Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Study of Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines
Conditions
Interventions
Ad26.COV2.S
BNT162b2
+4 more
Locations
10
United States
The Hope Clinic of Emory University
Decatur, Georgia, United States
University of Maryland Baltimore - Institute of Human Virology
Baltimore, Maryland, United States
NYU Langone Vaccine Center
New York, New York, United States
University of Rochester Medical Center - Vaccine Research Unit
Rochester, New York, United States
Cincinnati Children's Hospital Medical Center Vaccine Research Center
Cincinnati, Ohio, United States
University of Pittsburgh - Medicine - Infectious Diseases
Pittsburgh, Pennsylvania, United States
Start Date
May 28, 2021
Primary Completion Date
June 16, 2023
Completion Date
June 16, 2023
Last Updated
April 20, 2025
NCT06631287
NCT04565665
NCT04978571
NCT06082518
NCT07221162
NCT06679140
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions